Literature DB >> 9150081

Secondary amyloidosis in ankylosing spondylitis. A systematic survey of 137 patients using abdominal fat aspiration.

J Gratacos1, C Orellana, R Sanmarti, M Sole, A Collado, E Gomez-Casanovas, J de Dios Canete, J Munoz-Gomez.   

Abstract

OBJECTIVE: To assess the frequency and clinical significance of amyloid deposits in abdominal fat in patients with ankylosing spondylitis (AS).
METHODS: Abdominal subcutaneous fat aspiration (ASFA) by fine needle was performed in 137 unselected patients with AS of more than 5 years of disease evolution. A followup study was done of patients with amyloidosis in the abdominal fat (ASFA positive test) to evaluate the development of clinical amyloidosis.
RESULTS: In 10 (9M/1F) patients with AS, the ASFA revealed amyloid deposits (prevalence of 7%). Patients with AS and an ASFA+ test were older and had more active and severe disease than those without AS. Only 2 ASFA positive test patients had clinical amyloidosis at the time of the test. After a followup period of 2-10 yrs (mean 5.4 +/- 3.2 yrs), 3 more patients developed symptomatology due to amyloidosis. All 5 patients with clinical amyloidosis showed nephropathy, and proteinuria was found in each. The remaining patients did not develop clinical amyloidosis during followup.
CONCLUSION: Amyloid deposits in abdominal fat are not a rare finding in AS. A significant proportion of these patients do not develop clinical amyloidosis after a followup of several years. Thus, an ASFA + test in patients with AS is not always associated with a poor prognosis at least in the short term, although longer followup is required.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9150081

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

1.  Where has secondary amyloid gone?

Authors:  B P Hazenberg; M H van Rijswijk
Journal:  Ann Rheum Dis       Date:  2000-08       Impact factor: 19.103

Review 2.  Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports.

Authors:  E S Strobel; E Fritschka
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms].

Authors:  U Kiltz; M Rudwaleit; J Sieper; D Krause; J-F Chenot; A Stallmach; S Jaresch; U Oberschelp; E Schneider; B Swoboda; H Böhm; A Heiligenhaus; U Pleyer; W-H Böhncke; M Stemmer; J Braun
Journal:  Z Rheumatol       Date:  2014-09       Impact factor: 1.372

4.  Amyloid goiter in a case of systemic amyloidosis secondary to ankylosing spondylitis.

Authors:  P Cohan; S Hirschowitz; J Y Rao; S Tanavoli; A J Van Herle
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

5.  Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics.

Authors:  T M El Mansoury; B P C Hazenberg; S A El Badawy; A H Ahmed; J Bijzet; P C Limburg; M H van Rijswijk
Journal:  Ann Rheum Dis       Date:  2002-01       Impact factor: 19.103

6.  The burden of amyloidosis on the gastrointestinal tract of an ankylosing spondylitis patient.

Authors:  Levent Ozçakar; Seyfettin Köklü; Bayram Kaymak; Sedef Kuran; Zişan Sakaoğullari
Journal:  Clin Rheumatol       Date:  2003-10-16       Impact factor: 2.980

7.  Secondary amyloidosis in ankylosing spondylitis.

Authors:  Salim Dönmez; Ömer Nuri Pamuk; Gülsüm Emel Pamuk; Erkan Aydoğdu; Robert Inman
Journal:  Rheumatol Int       Date:  2013-01-03       Impact factor: 2.631

Review 8.  [Epidemiology and prognostic aspects of ankylosing spondylitis].

Authors:  J Braun
Journal:  Radiologe       Date:  2004-03       Impact factor: 0.635

9.  [Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations].

Authors:  U Kiltz; J Braun; A Becker; J-F Chenot; M Dreimann; L Hammel; A Heiligenhaus; K-G Hermann; R Klett; D Krause; K-F Kreitner; U Lange; A Lauterbach; W Mau; R Mössner; U Oberschelp; S Philipp; U Pleyer; M Rudwaleit; E Schneider; T L Schulte; J Sieper; A Stallmach; B Swoboda; M Winking
Journal:  Z Rheumatol       Date:  2019-12       Impact factor: 1.372

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.